Jaffar Khan

Jaffar Khan

Auto-generated profile, based on publicly available information

Jaffar Khan

Franciscan Health Lafayette, Lafayette, Indiana

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2006 in Neurology
Verified
Journal Article
Closed access
PDF file
JKJaffar Khan
Jaffar Khan
THTaylor B. Harrison
Taylor B. Harrison
MRMark M. Rich
Mark M. Rich
MMMarc Moss
Marc Moss
Objectives: To characterize the prevalence, time of onset, and cause of neuromuscular dysfunction in patients with severe sepsis. Methods: We conducted a prospective cohort study in which participants with severe sepsis underwent weekly neurologic examinations and nerve conduction studies (NCSs) within 72 hours of developing severe sepsis until intensive care unit (ICU) discharge. Electromyography was preformed if clinical weakness developed or if there was a significant reduction in nerve conduction response amplitudes. Results: Abnormal NCS were present upon enrollment in 63% of patients (31/48). The presence of abnormal baseline NCS was predictive of hospital mortality (55% vs 0% for patients with normal baseline NCS; p < 0.001). Development of acquired neuromuscular dysfunction could be predicted by NCS done on day 7. Twenty patients remained in the ICU long enough to have serial NCSs; 50% of these patients developed acquired neuromuscular dysfunction. Most patients with acquired neuromuscular dysfunction had electrophysiologic evidence of both critical illness myopathy and critical illness neuropathy. Conclusion: Changes in nerve conduction studies occur in the majority of patients early in the course of severe sepsis and predict the development of acquired neuromuscular dysfunction and mortality in intensive care unit patients. Most patients with acquired neuromuscular dysfunction after sepsis have both critical illness myopathy and critical illness neuropathy.

1 January 2008 in Critical Care Clinics
Verified
Journal Article
Closed access
JKJaffar Khan
Jaffar Khan
THTaylor B. Harrison
Taylor B. Harrison
MRMark M. Rich
Mark M. Rich

31 May 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
ZLZachary London
Zachary London
AMAbhimanyu Mahajan
Abhimanyu Mahajan
CCCarolyn Cahill
Carolyn Cahill
JKJaffar Khan
Jaffar Khan
ESErica A. Schuyler
Erica A. Schuyler
RPRaymond S. Price
Raymond S. Price
For many neurologic subspecialties, the fellowship application process begins early in the first half of the second year of neurology-specific training (PGY3 for adult neurology residents and PGY4 for child neurology residents). In 2019, the American Academy of Neurology (AAN) published a position statement recommending communication between fellowship candidates and training programs begin no sooner than March 1 of the penultimate year of training and that programs offer fellowship positions no sooner than August 1 of the final year of training. A few pilot subspecialties adopted this timeline for 2021 recruitment for positions beginning in 2022. All US-based AAN affiliated neurology and child neurology residents who recently completed the fellowship application process received a survey about their fellowship application experience. Of the 291 residents who responded to the survey, 96% agree that applications should not be submitted before March 1 of the penultimate year of training and 72% feel that August 1 of the final year is a reasonable time to begin offering positions. Nearly half (49%) of residents feel that there is too little time for subspecialty/clinical exposure prior to applying for fellowship and 88% feel the current process and timeline are stressful. Residents who applied to programs in pilot subspecialties report more time to choose, less stress, and a lower number of time-pressured offers. A vast majority of residents (89%) prefer to submit a single application through a centralized system. The survey results suggest that residents who just completed the fellowship application process agree with the AAN recommended timeline for all subspecialties, and that all neurology subspecialties should consider adopting a fellowship match. Programs can help facilitate a better fellowship application experience by providing earlier exposure to a broad range of neurologic subspecialties and ensure that residents are given opportunities to attend national meetings and participate in appropriately scoped scholarly endeavors.

1 June 2006
Verified
Journal Article
Closed access
JKJ Khan
J Khan
EBE L Burnham
E L Burnham
MMM Moss
M Moss

17 October 2017 in Neurology
Verified
Journal Article
Closed access
PDF file
JKJaffar Khan
Jaffar Khan
JBJames L. Bernat
James L. Bernat

10 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DMDana K. Mitchell
Dana K. Mitchell
KBKylee Brewster
Kylee Brewster
SMStavriani C. Makri
Stavriani C. Makri
JKJaffar Khan
Jaffar Khan
EAEric A. Albright
Eric A. Albright
WCWade Clapp
Wade Clapp
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of premature death among individuals with neurofibromatosis type 1 (NF1), and the transcriptional aberrations that precede malignant transformation and contribute to MPNST tumorigenesis remain poorly defined. Alterations involving CDKN2A and components of PRC2 have been implicated as early drivers of peripheral nerve sheath tumor (PNST) evolution, but these events do not occur in all MPNST. Accordingly, emerging data have begun to highlight the importance of molecular-based stratification to improve outcomes in patients with NF1–PNST. Experimental Design: In this study, we perform an integrated analysis of multiple, independent datasets obtained from human patients with NF1 to gain critical insights into PNST evolution and MPNST heterogeneity. Results: We show that delta-like noncanonical Notch ligand 1 (DLK1) is significantly increased in MPNST and provide evidence that DLK1 overexpression may precede histologic changes consistent with malignancy. In complementary analyses, we find that serum levels of DLK1 are significantly higher in both mice and humans harboring MPNST compared with those without malignancy. Importantly, although DLK1 expression is increased in MPNST overall, through the integration of multiple, independent datasets, we demonstrate that divergent levels of DLK1 expression distinguish MPNST subsets characterized by unique molecular programs and potential therapeutic vulnerabilities. Specifically, we show that overexpression of DLK1 is associated with the reactivation of embryonic signatures, an immunosuppressive microenvironment, and a worse overall survival in patients with NF1–MPNST. Conclusions: Collectively, our findings provide critical insights into MPNST tumorigenesis and support prospective studies evaluating the utility of DLK1 tissue and serum levels in augmenting diagnosis, risk assessment, and therapeutic stratification in the setting of NF1–PNST.